Ablexis Announces Licensing Agreement with Voyager Therapeutics
Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, today announced a license agreement with Voyager Therapeutics, Inc. (NASDAQ:VYGR). The non-exclusive license grants Voyager rights to use the AlivaMab Mouse for antibody drug discovery and development. Financial terms of the license include an upfront payment, development milestones and a royalty on product sales.
“Ablexis welcomes Voyager Therapeutics to the growing list of leading biopharmaceutical companies using the AlivaMab Mouse platform,” said Larry Green, Ph.D., Chief Executive Officer of Ablexis. “With access to our industry-leading platform, we are excited to work with the Voyager team to help further their mission to discover and develop gene therapies for patients with severe neurological diseases.”
The AlivaMab Mouse is designed to enable and optimize the efficient discovery and development of the next generation of human therapeutic antibodies. The platform has been validated for antibody drug discovery by Ablexis and partners in various formats including regular antibodies, bispecifics and CAR Ts and for a range of applications including:
- Sequence diverse panels of mAbs
- Epitope diverse panels of mAbs
- Challenging targets such as GPCRs
- Challenging design goals such as IC50 values of very low picomolar
About Ablexis, LLC
Ablexis, LLC created and commercializes the AlivaMab Mouse technology, a unique, patented next generation transgenic mouse platform for human therapeutic antibody discovery. Ablexis has non-exclusively licensed the AlivaMab Mouse technology to multiple companies, including global pharmaceutical companies, public and private biotechnology companies and other entities. Ablexis continues making the AlivaMab Mouse available via non-exclusive licenses. For more information, visit www.ablexis.com. For inquiries about licensing AlivaMab Mouse, contact us at firstname.lastname@example.org.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181023005025/en/